Science & Technology

Cellares Secures $255M in Funding, Plans Smart Factory in Bridgewater

Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, has secured $255 million in Series C funding. The company plans to use the money to launch the world’s first commercial-scale IDMO Smart Factory, which seamlessly integrates advanced robotics, purpose-built technology, and interconnected software. The 118,000-square-foot IDMO Smart Factory, located in Bridgewater, will be capable of producing 40,000 cell therapy batches per year. 

The fund was led by new investor Koch Disruptive Technologies. In connection with the financing, David Mauney, managing director at Koch Disruptive Technologies, will join the company’s board of directors. Global biopharmaceutical company and cell therapy leader Bristol Myers Squibb also participated in the round, alongside DFJ Growth, Willett Advisors and existing investors Eclipse, Decheng Capital, and 8VC. 

“Cell therapies have tremendous curative potential across a wide range of diseases. But right now, manufacturing by conventional CDMOs (contract development and manufacturing organization) is expensive, failure-prone, and impossible to scale,” said Mauney. “Cellares is driving transformation in the marketplace by combining an Industry 4.0 approach with full vertical integration. As the first IDMO, Cellares is empowering cell therapy companies to build viable businesses, remain competitive, and meet the needs of fast-growing patient populations.” 

By leveraging integrated technologies, IDMO Smart Factories can produce 10 times more cell therapy batches per year than traditional CDMO facilities, even with the same footprint and the same workforce. Cellares’ Smart Factories will be deployed around the world to enable the cell therapy industry to meet global patient demand. 

To access more business news, visit NJB News Now.

Related Articles: